Lymphoma & CLL Therapeutics

FDA approves tafasitamab in combination with lenalidomide as second-line treatment for patients with R/R DLBCL

On July 31, 2020, the U.S. Food and Drug Administration (FDA) approved tafasitamab in...

Ixazomib, rituximab, and dexamethasone in patients with relapsed or progressive Waldenström’s macroglobulinemia: Final analysis of the HOVON124/ECWM-R2 study

Waldenström’s macroglobulinemia (WM) is a...

Phase II study of tisagenlecleucel in patients with R/R FL meets its primary endpoint

On August 4, 2020, positive results were announced from the phase II ELARA trial (NCT03568461), investigating...

Results from phase I ALEXANDER study investigating the first CAR T-cell therapy, AUTO3, plus pembrolizumab to target both CD19 and CD22 in the treatment of R/R DLBCL

Available CD19 chimeric antigen...

Venetoclax and navitoclax for R/R ALL and lymphoblastic lymphoma

Despite the development of novel therapeutic and chemotherapeutic agents, a great percentage of patients with relapsed or refractory...

Results from the OAsis phase I/II trial on ibrutinib, venetoclax plus obinutuzumab in patients with newly diagnosed mantle cell lymphoma

During the 2020 European Hematology Association (EHA) Annual...

Acalabrutinib receives CHMP positive opinion for the treatment of patients with chronic lymphocytic leukemia

On 23 July, 2020, acalabrutinib received a positive opinion by the Committee for Medicinal...

Alemtuzumab plus CHOP in elderly patients with PTCL: Results from a phase III trial

Despite recent efforts to improve outcomes, survival in patients with peripheral T-cell lymphoma (PTCL) remains...